Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.

Transl Lung Cancer Res · 2024 · PMC11736605 · PMID 39830774

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP=0.09so close (0.05 < p ≤ 0.1)

9.3 months, HR =0.70; 95% CI, 0.51–0.96; P=0.02) symptom scales and showed a trend in delaying the GHS/QoL (5.0 vs. 4.8 months, HR =0.79; 95% CI, 0.58–1.07; P=0.09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.